


New TAP Compound in Development at ImmunoGen

Appendix A

- huMv9-6-DM1: CD33-positive tumors (AML)

Therapeutic Window for My9-6-DM1

Appendix A.



R.J. Lutz et al. *Proceedings of AACR-43, 912 (2002), Abstract 4518.*

Dose (days 12 through 15) conjugated calicheamicin

مکالمہ کے طور پر اپنی ملکیت کا اعلان کرنے والے ملکوں کی
لیے ایک بہت سی بحثیں موجود ہیں۔

卷之三

446 FEBRUARY 2005

Observations of the velocity of migration In 6200 other hatching
46,280 songbirds. These only were used as an independent sample. Compared
here to those which were tracked with a recover rate of 70.4%.

► Radiosonden werden während der Missionen über die Erde fliegen.



काले गोदान की विधि अनुसार देखा जाएगा।




100

1



Tijdschrift voor Nederlandse Taal- en Letterkunde 79(2) 2001

2



222

* 16 Apr 2015 produced by NEDLIB using the code of the University of Amsterdam

卷之三

088888888

Examples of TAPs currently in development

Appendix C

- SB-408075/huC242-DM1
colorectal
- huN901-DM1
lung
- My9-6-DM1
AML
- Herceptin-DM1
breast

My9-6-DM1 TAP

Biological Marker: CD33


For the treatment of acute myeloid leukemia (AML)

In preclinical development

Humanization of My9-6 using patented ImmunoGen technology

My9-6-DM1 cures HL-60 tumor xenografts

Appendix C



IMMUNOGEN, INC.

TAP Technology Platform: Summary

Appendix C

- Widely applicable for cancer huMAbs
- Generates product candidates with superior preclinical efficacy
- Incorporated into two product candidates currently in clinical trials:
 - SB-408075/ huC242-DM1 (GlaxoSmithKline)
 - huN901-DM1 (ImmunoGen/ British Biotech)
- TAPs under preclinical development include Herceptin®-DM1(Genentech), My9-6-DM1 (ImmunoGen)
- Agreements with Genentech, Abgenix, Millennium, and others to develop additional huMAb-DM1 TAPs
- Additional ImmunoGen TAPs are under development

IMMUNOGEN, INC.